Welcome to Markets Desk, here's what's moving the needle this afternoon.
The Federal Reserve has broken its long pause, voting unanimously to raise its benchmark rate by a quarter point, bringing it to a range of three point seven five to four percent. It's the first hike since July of twenty twenty three and the first policy move under Chairman Kevin Warsh, putting him directly at odds with President Trump, who has been publicly demanding cuts. Fed projections suggest officials are not anticipating this as a one-and-done move, which means CFOs across corporate America are right to be recalibrating their financing assumptions.
Shifting to semiconductors, Applied Materials announced a five billion dollar investment in India over the next decade, aimed at expanding research and development and deepening India's role in the global chip supply chain. For a sector already navigating export controls and geopolitical fragmentation, this signals that equipment makers are actively hedging their geographic exposure and betting on India as a long-term manufacturing anchor.
And in biotech, Viking Therapeutics is drawing serious attention from Wall Street analysts who see its dual-formulation weight loss drug, VK two seven three five, as a genuine differentiator in the GLP-one space. The rapid onset of weight loss and the oral and injectable options could carve out meaningful market share, provided phase three trial results hold up.
That's the tape. Markets Desk, signing off the floor.
